» Authors » Fiammetta Bozzani

Fiammetta Bozzani

Explore the profile of Fiammetta Bozzani including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 30
Citations 326
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Heck C, Kripke K, Dam A, Torres-Rueda S, Bozzani F, Obermeyer C, et al.
Health Res Policy Syst . 2024 Nov; 22(1):156. PMID: 39587579
Background: Costing and financing systematic implementation are recognized barriers to human immunodeficiency virus (HIV) prevention. In the absence of empiric implementation and economic data, perspectives from international stakeholders involved in...
2.
Diaconu K, Karat A, Bozzani F, McCreesh N, Falconer J, Voce A, et al.
Health Policy Plan . 2024 Aug; 39(10):1041-1054. PMID: 39215970
Tuberculosis infection prevention and control (TB IPC) measures are a cornerstone of policy, but measures are diverse and variably implemented. Limited attention has been paid to the health system environment,...
3.
Lamberti O, Terris-Prestholt F, Bustinduy A, Bozzani F
Trop Med Int Health . 2024 Aug; 29(10):859-868. PMID: 39095942
Female genital schistosomiasis is a chronic gynaecological disease caused by the waterborne parasite Schistosoma (S.) haematobium. It affects an estimated 30-56 million girls and women globally, mostly in sub-Saharan Africa...
4.
Lamberti O, Bozzani F, Kiyoshi K, Bustinduy A
Br Med Bull . 2024 Jan; 149(1):45-59. PMID: 38220571
Background: Female genital schistosomiasis (FGS) is a chronic gynaecological disease affecting girls and women in sub-Saharan Africa (SSA), caused by the parasite Schistosoma (S.) haematobium. FGS is associated with sexual...
5.
Yates T, Karat A, Bozzani F, McCreesh N, MacGregor H, Beckwith P, et al.
Antimicrob Steward Healthc Epidemiol . 2023 Jul; 3(1):e117. PMID: 37502244
In clinical settings where airborne pathogens, such as Mycobacterium tuberculosis, are prevalent, they constitute an important threat to health workers and people accessing healthcare. We report key insights from a...
6.
Castor D, Heck C, Quigee D, Telrandhe N, Kui K, Wu J, et al.
J Int AIDS Soc . 2023 Jul; 26 Suppl 2:e26110. PMID: 37439063
Introduction: Several low- and middle-income countries (LMICs) are preparing to introduce long-acting pre-exposure prophylaxis (LAP). Amid multiple pre-exposure prophylaxis (PrEP) options and constrained funding, decision-makers could benefit from systematic implementation...
7.
Giddings R, Indravudh P, Medley G, Bozzani F, Gafos M, Malhotra S, et al.
Pharmacoeconomics . 2023 Mar; 41(6):693-707. PMID: 36988896
Background: The HIV epidemic remains a major public health problem. Critical to transmission control are HIV prevention strategies with new interventions continuing to be developed. Mathematical models are important for...
8.
Torres-Rueda S, Terris-Prestholt F, Gafos M, Indravudh P, Giddings R, Bozzani F, et al.
Pharmacoeconomics . 2023 Mar; 41(7):787-802. PMID: 36905570
Background And Objective: Although HIV prevention science has advanced over the last four decades, evidence suggests that prevention technologies do not always reach their full potential. Critical health economics evidence...
9.
Perera S, Parkhurst J, Diaconu K, Bozzani F, Vassall A, Grant A, et al.
Health Policy Plan . 2022 Jul; 37(9):1177-1187. PMID: 35904279
To better understand and plan health systems featuring multiple levels and complex causal elements, there have been increasing attempts to incorporate tools arising from complexity science to inform decisions. The...
10.
Pearson C, Bozzani F, Procter S, Davies N, Huda M, Jensen H, et al.
PLoS Med . 2022 May; 19(5):e1003990. PMID: 35507911
[This corrects the article DOI: 10.1371/journal.pmed.1003815.].